UltraTech’s Capex To Drive Cement Capacity Consolidation, Say Analysts; Shares Fall
Analysts expect UltraTech Cement Ltd.'s Rs 12,886-crore capex plan to trigger a consolidation of capacity share toward large producers.
“The top five players accounted for 41% of industry capacity in FY14. Their share is likely to rise to 52% in FY25,” CLSA said in a report.
According to Macquarie Research, industry consolidation is “positive in the medium term”.
This comes as the Aditya Birla Group flagship aims to increase its capacity by 22.6 million tonnes through brown field and green field expansions by the fiscal ending March 2025. That, along with its ongoing and proposed expansion plans, would take its total production capability to 159 MTPA by FY25.
The analysts also see the capacity expansion plan to strengthen UltraTech Cement's pole position.
Shares of the company were down as much as 5.6% as of 1:38 p.m., the most in 12 weeks, on Friday. Of the 48 analysts tracking the stock, 41 maintain a ‘buy', five suggest a ‘hold' and two recommend a ‘sell', according to Bloomberg data. The average of the 12-month consensus price target implies a 33.6% upside.
The stock's trading volume is 7.7 times the 30-day average.
Here's what analysts have to say about UltraTech Cement's capex plan.
CLSA
Maintains ‘buy', cuts target price to Rs 7,640 apiece from Rs 7,980.
Capacity expansion to reinforce leadership, but industry dynamics uncertain.
Capacity expansion for capex implies a cost of $76 a tonne, much lower than $100-110-a-tonne benchmark.
The top five players accounted for 41% of industry capacity in FY14.
Top five players share likely to rise to 52% in FY25.
Leadership reinforced through RoCE-accretive expansion.
Better placed in an otherwise difficult macro.
Estimates UltraTech Cement will continue to generate positive free cash flow even with elevated capex.
See risk-reward as attractive.
Tweaks FY23-25 Ebitda estimates by 2-3% on slightly lower price assumptions.
Goldman Sachs
Maintains ‘buy' with a target price of Rs 7,070 apiece.
UltraTech will remain the clear No. 1 domestic cement producer.
Announces capacity expansion, confirming its leadership position.
Announcement points to a consolidation of capacity share towards the large producers.
Preliminary calculations suggest post-tax RoCE of at least 12.5% for these assets even in a low-profitability environment.
Recently turned cautious on the sector with UltraTech the only ‘buy'.
Macquarie Research
Cement demand outlook remains robust due to focus on infrastructure, recovery in urban housing and private capex.
Cement price volatility could rise.
Industry consolidation is positive in the medium term.
Key to track the response from other cement players, including Shree Cement Ltd., The Ramco Cements Ltd. and Dalmia Bharat Ltd.
JPMorgan
Maintains ‘neutral' with a target price of Rs 6,040 apiece.
Industry entering a new capacity addition spiral in response to new entrant.
A new capex plan would prepone company's 160-MTPA plan by 5 years.
It does a create the risk of further additions.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.